AR104984A1 - Compuestos selectivos para pyy y sus usos - Google Patents
Compuestos selectivos para pyy y sus usosInfo
- Publication number
- AR104984A1 AR104984A1 ARP160101755A ARP160101755A AR104984A1 AR 104984 A1 AR104984 A1 AR 104984A1 AR P160101755 A ARP160101755 A AR P160101755A AR P160101755 A ARP160101755 A AR P160101755A AR 104984 A1 AR104984 A1 AR 104984A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyy
- compounds
- application
- selective compounds
- refers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 abstract 1
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
Abstract
La solicitud hace referencia a compuestos para PYY con las modificaciones de aminoácidos 7Lys, 30Trp y 31Leu y además 22Ile o 28Tyr, y sus derivados. El compuesto de la solicitud corresponde a agonistas del receptor Y2 selectivo. La solicitud también hace referencia a composiciones farmacéuticas que comprenden dichos compuestos para PYY y excipientes farmacéuticamente aceptables, como también al uso médico de los compuestos para PYY.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171785 | 2015-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104984A1 true AR104984A1 (es) | 2017-08-30 |
Family
ID=53404384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101755A AR104984A1 (es) | 2015-06-12 | 2016-06-13 | Compuestos selectivos para pyy y sus usos |
Country Status (18)
Country | Link |
---|---|
US (1) | US10005824B2 (es) |
EP (1) | EP3307768A1 (es) |
JP (1) | JP6731958B2 (es) |
KR (1) | KR102476550B1 (es) |
CN (1) | CN107849110B (es) |
AR (1) | AR104984A1 (es) |
AU (1) | AU2016275735B2 (es) |
BR (1) | BR112017025108A2 (es) |
CA (1) | CA2988500A1 (es) |
IL (1) | IL255781B (es) |
MA (1) | MA43205A (es) |
MX (1) | MX2017015105A (es) |
MY (1) | MY187047A (es) |
RU (1) | RU2726777C2 (es) |
SA (1) | SA517390445B1 (es) |
TW (1) | TWI694082B (es) |
WO (1) | WO2016198682A1 (es) |
ZA (1) | ZA201707782B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5902194B2 (ja) | 2010-12-16 | 2016-04-13 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストとn−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物 |
ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
MX369818B (es) | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
RU2019100423A (ru) | 2016-06-14 | 2020-07-14 | ПЬЮРСЁРКЛ ЮЭсЭй ИНК. | Стевиолгликозидные композиции, способы получения и применения |
JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー/エス | Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物 |
TWI749381B (zh) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
US20220280611A1 (en) * | 2019-08-07 | 2022-09-08 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid |
MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CA3185637A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ265452A (en) * | 1993-03-29 | 1997-09-22 | Univ Cincinnati | Analogues of peptide yy, dimers and pharmaceutical compositions |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
CA2271788A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
CA2334298C (en) | 1998-06-08 | 2008-01-08 | Schering Corporation | Neuropeptide y5 receptor antagonists |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
JP2004515533A (ja) | 2000-12-14 | 2004-05-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 代謝障害を治療するためのペプチドyyおよびペプチドyyアゴニスト |
US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7811989B2 (en) | 2003-01-17 | 2010-10-12 | Ipsen Pharma S.A.S. | Peptide YY analogs |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
CN101380476A (zh) | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
RU2006120077A (ru) | 2003-12-18 | 2008-01-27 | Ново Нордиск А/С (DK) | Аналоги глюкагоноподобного пептида-1 (glp-1), связанные с альбуминоподобными агентами |
CA2555894A1 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
CN103897066A (zh) | 2004-02-11 | 2014-07-02 | 安米林药品有限责任公司 | 具有可选择特性的杂合多肽 |
JP2007531714A (ja) | 2004-03-17 | 2007-11-08 | 7ティーエム ファーマ エイ/エス | 治療的介入のためのy2/y4選択性レセプターアゴニスト |
CN1953763A (zh) | 2004-03-17 | 2007-04-25 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y4选择性受体激动剂 |
EP2060266B1 (en) | 2004-03-17 | 2011-08-10 | 7TM Pharma A/S | Y4 selective receptor agonist PP2-36 for therapeutic interventions |
EA011860B1 (ru) | 2004-03-17 | 2009-06-30 | 7ТиЭм ФАРМА А/С | Селективные агонисты рецептора y2 для терапевтического воздействия |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
US7994119B2 (en) | 2004-07-19 | 2011-08-09 | University Of Cincinnati | Compounds for control of appetite |
SI1786400T1 (sl) | 2004-08-12 | 2009-08-31 | Quest Pharmaceutical Services | Farmacevtski sestavki za dajanje biološko aktivnih spojin z nadzorovanim sproščanjem |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2614619A1 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
MX2007016024A (es) | 2005-07-18 | 2008-03-10 | Novo Nordisk As | Peptidos novedosos para el uso en el tratamiento contra la obesidad. |
JP2009508886A (ja) | 2005-09-21 | 2009-03-05 | 7ティーエム ファーマ エイ/エス | 治療的介入のためのy2選択性レセプターアゴニスト |
EP1934254A1 (en) | 2005-09-21 | 2008-06-25 | 7TM Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
WO2007065808A2 (en) | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
WO2007068718A1 (en) | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
US20090186817A1 (en) | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
BRPI0715469A2 (pt) | 2006-07-11 | 2013-03-12 | Qps Llc | composiÇÕes farmacÊuticas para a liberaÇço sustentada de peptÍdeos |
GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
CN101970475A (zh) | 2007-07-09 | 2011-02-09 | 帝国改革有限公司 | 人类胰多肽(hpp)类似物及其对摄食行为的作用 |
ES2532116T3 (es) | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Péptidos derivados con A-B-C-D y sus usos terapéuticos |
KR20100059864A (ko) * | 2007-09-11 | 2010-06-04 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 trap-14 |
WO2009042922A2 (en) | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
CA2723855A1 (en) | 2008-05-16 | 2009-11-19 | Novo Nordisk A/S | Long-acting y2 and/or y4 receptor agonists |
US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
KR20110097807A (ko) | 2008-11-05 | 2011-08-31 | 에프. 호프만-라 로슈 아게 | 뉴로펩티드-2-수용체(y-2r) 작용제 및 이의 용도 |
CA2752608A1 (en) | 2009-02-20 | 2010-08-26 | Ipsen Pharma S.A.S. | Cytotoxic conjugates having neuropeptide y receptor binding compound |
WO2011033068A1 (en) | 2009-09-18 | 2011-03-24 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
WO2011058165A1 (en) * | 2009-11-13 | 2011-05-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
EP2560675A1 (en) | 2010-04-20 | 2013-02-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
US20150141336A1 (en) | 2012-05-29 | 2015-05-21 | Novo Nordisk A/S | Pancreatic Peptide Compounds and Use |
TW201534616A (zh) | 2013-05-02 | 2015-09-16 | Glaxosmithkline Ip Dev Ltd | 治療性胜肽 |
JP6629198B2 (ja) * | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
MX369818B (es) * | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
-
2016
- 2016-06-13 AR ARP160101755A patent/AR104984A1/es unknown
- 2016-06-13 TW TW105118511A patent/TWI694082B/zh active
- 2016-06-13 EP EP16734567.7A patent/EP3307768A1/en active Pending
- 2016-06-13 JP JP2017564450A patent/JP6731958B2/ja active Active
- 2016-06-13 AU AU2016275735A patent/AU2016275735B2/en active Active
- 2016-06-13 MY MYPI2017704318A patent/MY187047A/en unknown
- 2016-06-13 KR KR1020177037622A patent/KR102476550B1/ko active IP Right Grant
- 2016-06-13 MA MA043205A patent/MA43205A/fr unknown
- 2016-06-13 BR BR112017025108A patent/BR112017025108A2/pt active Search and Examination
- 2016-06-13 WO PCT/EP2016/063429 patent/WO2016198682A1/en active Application Filing
- 2016-06-13 RU RU2017145348A patent/RU2726777C2/ru active
- 2016-06-13 CA CA2988500A patent/CA2988500A1/en not_active Withdrawn
- 2016-06-13 MX MX2017015105A patent/MX2017015105A/es unknown
- 2016-06-13 CN CN201680045277.3A patent/CN107849110B/zh active Active
-
2017
- 2017-06-28 US US15/635,456 patent/US10005824B2/en active Active
- 2017-11-16 ZA ZA2017/07782A patent/ZA201707782B/en unknown
- 2017-11-20 IL IL255781A patent/IL255781B/en unknown
- 2017-11-30 SA SA517390445A patent/SA517390445B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
CN107849110B (zh) | 2021-11-26 |
RU2017145348A3 (es) | 2019-09-09 |
AU2016275735B2 (en) | 2020-02-06 |
EP3307768A1 (en) | 2018-04-18 |
MY187047A (en) | 2021-08-27 |
RU2017145348A (ru) | 2019-07-12 |
IL255781A (en) | 2018-04-30 |
JP2018522843A (ja) | 2018-08-16 |
SA517390445B1 (ar) | 2020-12-21 |
KR20180019616A (ko) | 2018-02-26 |
RU2726777C2 (ru) | 2020-07-15 |
MX2017015105A (es) | 2018-05-07 |
US20170313750A1 (en) | 2017-11-02 |
JP6731958B2 (ja) | 2020-07-29 |
US10005824B2 (en) | 2018-06-26 |
TWI694082B (zh) | 2020-05-21 |
KR102476550B1 (ko) | 2022-12-13 |
IL255781B (en) | 2021-10-31 |
BR112017025108A2 (pt) | 2018-07-31 |
WO2016198682A1 (en) | 2016-12-15 |
MA43205A (fr) | 2018-09-19 |
CN107849110A (zh) | 2018-03-27 |
CA2988500A1 (en) | 2016-12-15 |
AU2016275735A1 (en) | 2017-12-07 |
TW201710284A (zh) | 2017-03-16 |
ZA201707782B (en) | 2019-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
UY39706A (es) | Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue | |
SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
UY36124A (es) | Derivados de carboxamida | |
AR096338A1 (es) | (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |